Safety and efficacy of a genetic vaccine targeting telomerase plus chemotherapy for the therapy of canine B-cell lymphoma

Human Gene Therapy

Volumn 24, Issue 8, 2013, Pages 728-738

  Gavazza, Alessandra ^a   Lubas, George ^a   Fridman, Arthur ^b   Peruzzi, Daniela ^c   Impellizeri, Joseph A ^d   Luberto, Laura ^e,f   Marra, Emanuele ^f   Roscilli, Giuseppe ^f   Ciliberto, Gennaro ^g   Aurisicchio, Luigi ^f,h  

^a UNIVERSITY OF PISA   (Italy)

^b MERCK RESEARCH LABORATORIES   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d Veterinary Specialty Center of the Hudson Valley   (United States)

^e UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^f Takis srl   (Italy)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h Grande Ospedale Metropolitano   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; MELPHALAN; PREDNISONE; TELOMERASE REVERSE TRANSCRIPTASE; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; FEMALE; FEVER; FOLLOW UP; HEMATOLOGICAL PARAMETERS; IMMUNE RESPONSE; MAINTENANCE CHEMOTHERAPY; MALE; NONHUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; DOGS; FEMALE; GENE TARGETING; IMMUNOTHERAPY; LYMPHOMA, B-CELL; MALE; REAL-TIME POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TELOMERASE;

EID: 84882415261     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2013.112     Document Type: Article

References (49)

1. Argyle, D.J., and Nasir, L. (2003). Telomerase: a potential diagnostic and therapeutic tool in canine oncology. Vet. Pathol. 40, 1-7.
2. Aurisicchio, L., and Ciliberto, G. (2011a). Emerging cancer vaccines: the promise of genetic vectors. Cancers 3, 3687-3713.
3. Aurisicchio, L., and Ciliberto, G. (2011b). Harnessing the Immune System to Fight Cancer: The Promise of Genetic Cancer Vaccines. Cancer Treatment/Book 1. Intech, Rijeka, Croatia.
4. Aurisicchio, L., and Ciliberto, G. (2012). Genetic cancer vaccines: current status and perspectives. Expert Opin. Biol. Ther. 12, 1043-1058.
5. Aurisicchio, L., Mennuni, C., Giannetti, P., et al. (2007). Immunogenicity and safety of a DNA prime/adenovirus boost vaccine against rhesus CEA in nonhuman primates. Int. J. Cancer 120, 2290-2300.
6. Bergman, P.J. (2007). Anticancer vaccines. Vet. Clin. North Am. Small Anim. Pract. 37, 1111-1119.
7. Bracci, L., Moschella, F., Sestili, P., et al. (2007). Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin. Cancer Res. 13, 644-653.
8. Burnett, R.C., Vernau, W., Modiano, J.F., et al. (2003). Diagnosis of canine lymphoid neoplasia using clonal rearrangements of antigen receptor genes. Vet. Pathol. 40, 32-41.
9. Burton, J.H., Mitchell, L., Thamm, D.H., et al. (2011). Low-dose cyclophosphamide selectively decreases regulatory T cells and inhibits angiogenesis in dogs with soft tissue sarcoma. J. Vet. Intern. Med. 25, 920-926.
10. Couto, C.G. (2009). Lymphoma in the cat and dog, In: Small Animal Internal Medicine. 4th edition. R.W. Nelson and C.G. Couto, eds. (Saunders, Elsevier, St. Louis, MO) pp. 1174-1186.
11. Chun, R. (2009). Lymphoma: which chemotherapy protocol and why? Top. Companion Anim. Med. 24, 157-162.
12. Dharmapuri, S., Peruzzi, D., Mennuni, C., et al. (2009). Coadministration of telomerase genetic vaccine and a novel TLR9 agonist in nonhuman primates. Mol. Ther. 17, 1804-1813.
13. Dudley, M.E., Wunderlich, J.R., Robbins, P.F., et al. (2002). Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 298, 850-854.
14. Fattori, E., Aurisicchio, L., Zampaglione, I., et al. (2009). ErbB2 genetic cancer vaccine in nonhuman primates: relevance of single nucleotide polymorphisms. Hum. Gene Ther. 20, 253- 265.
15. Finnefrock, A.C., Tang, A., Li, F., et al. (2009). PD-1 blockade in rhesus macaques: impact on chronic infection and prophylactic vaccination. J. Immunol. 182, 980-987.
16. Fournel-Fleury, C., Magnol, J.P., Bricaire, P., et al. (1997). Cytohistological and immunological classification of canine malignant lymphomas: comparison with human non-Hodgkin's lymphomas. J. Comp. Pathol. 117, 35-59.
17. Gavazza, A., Presciuttini, S., Barale, R., et al. (2001). Association between canine malignant lymphoma, living in industrial areas, and use of chemicals by dog owners. J. Vet. Intern. Med. 15, 190-195.
18. Gavazza, A., Sacchini, F., Lubas, G., et al. (2009). Clinical, laboratory, diagnostic and prognostic aspects of canine lymphoma: a restrospective study. Comp. Clin. Pathol. 18, 291-299.
19. Ghiringhelli, F., Menard, C., Puig, P.E., et al. (2007). Metronomic cyclophosphamide regimen selectively depletes CD4 + CD25 + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 56, 641-648.
20. Goulart, M.R., Pluhar, G.E., and Ohlfest, J.R. (2012). Identification of myeloid derived suppressor cells in dogs with naturally occurring cancer. PLoS One 7, e33274.
21. Hayes, H.M., Tarone, R.E., Cantor, K.P., et al. (1991). Casecontrol study of canine malignant lymphoma: positive association with dog owner's use of 2, 4-dichlorophenoxyacetic acid herbicides. J. Natl. Cancer Inst. 83, 1226-1231.
22. Hoos, A., Parmiani, G., Hege, K., et al. (2007). A clinical development paradigm for cancer vaccines and related biologics. J. Immunother. 30, 1-15.
23. Lurie, D.M., Gordon, I.K., Théon, A.P., et al. (2009). Sequential low-dose rate half-body irradiation and chemotherapy for the treatment of canine multicentric lymphoma. J. Vet. Intern. Med. 23, 1064-1070.
24. Marconato, L. (2011). The staging and treatment of multicentric high-grade lymphoma in dogs: a review of recent developments and future prospects. Vet. J. 188, 34-38.
25. Marconato, L., Gelain, M.E., and Comazzi, S. (2013). The dog as a possible animal model for human non-Hodgkin lymphoma: a review. Hematol. Oncol. 31, 1-9.
26. Meyerson, M., Counter, C.M., Eaton, E.N., et al. (1997). hEST2, the putative human telomerase catalytic subunit gene, is upregulated in tumor cells and during immortalization. Cell 90, 785-795.
27. Messaoudi, I., Estep, R., Robinson, B., and Wong, S.W. (2011). Nonhuman primate models of human immunology. Antioxid. Redox Signal. 14, 261-273.
28. Mitchell, L., Dow, S.W., Slansky, J.E., and Biller, B.J. (2012a). Induction of remission results in spontaneous enhancement of anti-tumor cytotoxic T-lymphocyte activity in dogs with B cell lymphoma. Vet. Immunol. Immunopathol. 145, 597-603.
29. Mitchell, L., Thamm, D.H., and Biller, B.J. (2012b). Clinical and immunomodulatory effects of toceranib combined with lowdose cyclophosphamide in dogs with cancer. J. Vet. Intern. Med. 26, 355-362.
30. Nakamura, T.M., Morin, G.B., Chapman, K.B., et al. (1997). Telomerase catalytic subunit homologs from fission yeast and human. Science. 277, 955-959.
31. Nasir, L. (2008). Telomeres and telomerase: biological and clinical importance in dogs. Vet. J. 175, 155-163.
32. Nasir, L., Devlin, P., McKevitt, T., et al. (2001). Telomere lengths and telomerase activity in dog tissues: a potential model system to study human telomere and telomerase biology. Neoplasia 3, 351-359.
33. Nistico, P., Capone, I., Palermo, B., et al. (2009). Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. Int. J. Cancer 124, 130-139.
34. O'Connor, C.M., Sheppard, S., Hartline, C.A., et al. (2012). Adoptive T-cell therapy improves treatment of canine non- Hodgkin lymphoma post chemotherapy. Sci. Rep. 2, 249.
35. Paoloni, M., and Khanna, C. (2008). Translation of new cancer treatments from pet dogs to humans. Nat. Rev. Cancer 8, 147-156.
36. Peruzzi, D., Gavazza, A., Mesiti, G., et al. (2010). A vaccine targeting telomerase enhances survival of dogs affected by B-cell lymphoma. Mol. Ther. 18, 1559-1567.
37. Peruzzi, D., Mesiti, G., Ciliberto, G., et al. (2010). Telomerase and HER-2/neu as targets of genetic cancer vaccines in dogs. Vaccine 28, 1201-1208.
38. Ranieri, G., Gadaleta, C.D., Patruno, R., et al. (2013). A model of study for human cancer: Spontaneous occurring tumors in dogs. Biological features and translation for new anticancer therapies. Crit. Rev. Oncol. Hematol. pii: S1040- 8428(13)00065-6.
39. Simon, D., Moreno, S.N., Hirschberger, J., et al. (2008). Efficacy of a continuous, multiagent chemotherapeutic protocol versus a short-term single-agent protocol in dogs with lymphoma. J. Am. Vet. Med. Assoc. 232, 879-885.
40. Sorenmo, K.U., Krick, E., Coughlin, C.M., et al. (2011). CD40- activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non- Hodgkin's lymphoma. PLoS One 6, e24167.
41. Staprans, S.I., Feinberg, M.B., Shiver, J.W., and Casimiro, D.R. (2010). Role of nonhuman primates in the evaluation of candidate AIDS vaccines: an industry perspective. Curr. Opin. HIV AIDS 5, 377-385.
42. Stein, W.D., Gulley, J.L., Schlom, J., et al. (2011). Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin. Cancer Res. 17, 907-917.
43. Ugel, S., Scarselli, E., Iezzi, M., et al. (2010). Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerasespecific T lymphocytes. Blood 115, 1374-1384.
44. Vail, D.M. (2010). Hematopoietic tumors - lymphoma. In Textbook of Veterinary Internal Medicine. 7th edition. Vol. 2. S. J. Ettinger and E. C. Feldman, eds. (Saunders, Elsevier, St. Louis, MO) pp. 2083-2100.
45. Valli, V.E., Vernau, W., de Lorimier, L.P., et al. (2006). Canine indolent nodular lymphoma. Vet. Pathol. 43, 241-256.
46. van der Most, R.G., Currie, A., Robinson, B.W., and Lake, R.A. (2006). Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity. Cancer Res. 66, 601-604.
47. Willmann, M., Mullauer, L., Guija de Arespacochaga, A., et al. (2008). Pax5 immunostaining in paraffin-embedded sections of canine non-Hodgkin lymphoma: A novel canine pan pre-B- and B-cell marker. Vet. Immunol. Immunopathol. 128, 359-365.
48. Willmann, M., Mullauer, L., Guija de Arespacochaga, A., et al. (2009). Pax5 immunostaining in paraffin-embedded sections of canine non-Hodgkin lymphoma: a novel canine pan pre-B- and B-cell marker. Vet. Immunol. Immunopathol. 128, 359-365.
49. Yazawa, M., Okuda, M., Setoguchi, A., et al. (1999). Measurement of telomerase activity in dog tumors. J. Vet. Med. Sci. 61, 1125-1129.